First Light Asset Management LLC Sells 79,249 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

First Light Asset Management LLC lessened its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 868,882 shares of the biotechnology company’s stock after selling 79,249 shares during the quarter. AnaptysBio comprises 1.1% of First Light Asset Management LLC’s investment portfolio, making the stock its 25th largest position. First Light Asset Management LLC owned about 2.86% of AnaptysBio worth $11,504,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock worth $24,411,000 after buying an additional 143,584 shares in the last quarter. Geode Capital Management LLC raised its position in AnaptysBio by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company’s stock valued at $6,444,000 after purchasing an additional 21,196 shares in the last quarter. Victory Capital Management Inc. lifted its stake in AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock worth $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of AnaptysBio by 1.6% in the 4th quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock worth $3,563,000 after purchasing an additional 4,242 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of AnaptysBio by 10.0% during the 4th quarter. Northern Trust Corp now owns 219,986 shares of the biotechnology company’s stock valued at $2,913,000 after buying an additional 20,073 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have commented on ANAB. Wolfe Research initiated coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price target on the stock. JPMorgan Chase & Co. lifted their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “neutral” rating and set a $22.00 price objective on shares of AnaptysBio in a research note on Tuesday, March 4th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a report on Monday, March 3rd. Finally, Wedbush restated an “outperform” rating and set a $40.00 target price on shares of AnaptysBio in a report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.63.

AnaptysBio Stock Up 0.4 %

Shares of AnaptysBio stock opened at $20.70 on Monday. The business has a 50 day moving average of $17.92 and a 200 day moving average of $19.45. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $41.31. The company has a market cap of $634.81 million, a PE ratio of -3.40 and a beta of -0.09.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.89. The business had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has authorized a share repurchase program on Monday, March 24th that permits the company to buyback $75.00 million in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.